As. Oncogene. 2008;27:4969?2. 36. Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH, et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific prognostic markers. Eur Urol. 2012;61:1245?6. 37. Beukers W, Kandimalla R, Masius R, Vermeij M, Kranse R, Leenders G, et al. Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer. Mod Pathol. 2015;28:515?2. 38. Yamamoto M, Cid E, Bru S, Yamamoto F. Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers. PLoS One. 2011;6, e17149. 39. Dunwell T, Hesson L, Rauch TA, Wang L, Clark RE, Dallol A, et al. A genomewide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer. 2010;9:44. 40. Shukla A, Chaturvedi N, Ahrens A, Cutucache C, Mittal A, Bierman P, et al. Stromal tumor microenvironment in chronic lymphocytic leukemia: regulation of leukemic progression. J Leuk (Los Angel). 2013;1:113. 41. Musialik E, Bujko M, Kober P, Wypych A, Gawle-Krawczyk K, Matysiak M, et al. Promoter methylation and expression levels of selected hematopoietic genes in pediatric B-cell acute lymphoblastic leukemia. Blood Res. 2015;50:26?2. 42. Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ. Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer. 2007;7:519?0. 43. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem. 2012;287:31666?3. 44. Muggen AF, Pillai SY, Kil LP, van Zelm MC, van Dongen JJ, Hendriks RW, et al. Basal Ca (2+) signalling is particularly increased in mutated chronic lymphocytic leukemia. Leukemia. 2015;29:321?. 45. Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, et al. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood. 2011;117:862?1. 46. Grcevi D, Marusi A, Grahovac B, Jaksi B, Kusec R. Expression of bone morphogenetic proteins in acute promyelocytic leukemia before and after combined all trans-retinoic acid and cytotoxic treatment. Leuk Res. 2003;27:731?. 47. Dzietczenia J, Wr el T, Jawiec B, Mazur G, Butrym A, Porba R, et al. Expression of bone morphogenetic proteins (BMPs) receptors in patients with B-cell chronic lymphocytic leukemia (B-CLL). Int J Lab Hematol. 2010;32:e217?1. 48. Gilboa L, Nohe A, Geissend fer T, Sebald W, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/8627573 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/22316373 Henis YI, Knaus P. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell. 2000;11:1023?5. 49. Chen D, Ji X, Harris MA, Feng JQ, Karsenty G, Celeste AJ, et al. Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J Cell Biol. 1998;142:295?05.50. Hanoun Letrozole M, Eisele L, Suzuki M, Greally J, Hu�ttmann A, Aydin S, et al. Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. PLoS One. 2012;7:e34347. 51. Yang MY, Chang JG, Lin PM, Tang KP, Chen YH, Lin HY, et al. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci. 2006;97:1298?07. 52. Liu Y, Miao Y, Wang J, L.